share_log

Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18

Moomoo 24/7 ·  Apr 3 09:32

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $25 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment